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their trust on quality (better medical cares, drugs and equipments), and also doctors
may use cost-saving strategies such as continuous prescriptions to help them. CON-
CLUSIONS: The attributes for GERD outpatients’ choices of accessing medical facili-
ties have been identiﬁ ed. Participants with different socioeconomic backgrounds in 
Southern Taiwan are aware of the increasing OPP, but the current OPP does not seem 
to impact on the affordability and accessibility of treatment. Future study is going to 
determine the relative importance of attributes and how different OPP can inﬂ uence
on decision making.
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EXAMINATION OF PROTON PUMP INHIBITOR (PPI) 
UTILIZATION AMONG GASTROESOPHAGEAL REFLUX (GERD) 
PATIENTS USING ELECTRONIC MEDICAL RECORDS (EMR)
Mody R1, Meissner BL2, Shaheen N3
1Takeda Pharmaceuticals North America, Inc, Deerﬁ eld, IL, USA, 2Xcenda, Palm Harbor, FL, 
USA, 3University of North Carolina, Chapel Hill, NC, USA
OBJECTIVES: To examine PPI utilization among patients with non-erosive GERD
(NERD), erosive esophagitis (EE) and Barrett’s esophagus (BE). METHODS: We
conducted an observational cohort study using EMRs obtained from a fully integrated 
health delivery system located in the mid-Atlantic region of the US. Incident cases of 
BE, EE, and NERD were identiﬁ ed between July 1, 2004–January 25, 2007. Patients 
were required to have encounter data for 6 months before and 12 months following 
their index diagnosis. Frequency of PPI use, time to PPI initiation, dosing frequency,
and switching patterns among the three cohorts at 52 weeks post diagnosis were
compared using NERD as the reference group. RESULTS: 12,273 patients met the 
inclusion criteria and included 79.6% NERD, 17.9% EE and 2.3% BE patients. A 
higher proportion of NERD and EE patients received a PPI as their initial pharmaco-
logic therapy (90.5% and 92.2%; p  0.0140) compared to 70.5% (p  0.0001) of 
BE patients. Greater than 90% of NERD and EE (p  0.0001) patients started initial
PPI therapy within 8 weeks post diagnosis compared to 71.6% (p  0.0001) of BE
patients. Majority of patients were prescribed once daily PPI therapy [NERD 79.4%;
BE 68.2% (p  0.0001); EE 73.6% (p  0.0001)] with a substantial proportion of 
patients on twice daily therapy [NERD 12.3%; BE 31.3% (p  0.0001); EE 15.2% 
(p  0.0003)]. Switching among initial PPI therapy occurred more often within BE 
patients (14.4%; p  0.0083) as compared to NERD and EE patients (9.0%, 9.3%; 
p  0.6896). There were no signiﬁ cant differences in patients reducing their PPI fre-
quency from twice daily to once daily therapy (NERD 24.5%, BE 18.5%, EE 25.7%).
CONCLUSIONS: A substantial proportion of patients with GERD are on twice daily 
PPI regimen. Switching between various PPI agents is common among GERD patients.
Future research should focus on the clinical and economic implications of twice daily 
PPI use and switching among PPIs.
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OBJECTIVES: To retrospectively examine patterns of PPI treatment in commercially
insured adults (q18 years of age) with selected upper gastrointestinal conditions.
METHODS: Patients were selected if they were newly dispensed a PPI in 2003 or
2004 (ﬁ rst PPI claim is “index date”) and were continuously enrolled in the 12 months
pre- and post-index. Based on ICD-9 CM diagnosis codes, four disease cohorts were
constructed: GERD, GERD-like symptoms (787.1), Erosive Esophagitis (EE), and
Barrett’s Esophagus (BE). Post-index length of treatment (LOT) was estimated as the 
cumulative days of index PPI therapy dispensed. Patients were considered “adherent” 
if the medication possession ratio (LOT/365 days) was q80%. Discontinuation of PPI 
medication was deﬁ ned as 90 days without available treatment. PPI adherence, dis-
continuation and LOT were compared between the four subgroups. RESULTS: The 
study population included 138,598 patients (91.7% GERD; 1.6% GERD-like symp-
toms; 4.1% EE; 2.7% BE). Mean (SD) number of reﬁ lls of index PPI for patients with
GERD-like symptoms, GERD, EE and BE were 2.9 (3.3), 3.2 (3.4), 4.1 (3.6) and 4.2 
(3.6), respectively (p  0.01). LOT was signiﬁ cantly (p  0.01) longer for BE [197.4
days (120.9)], EE [194.9 (121.4)], and GERD patients [154.3 (116.6)] compared to 
patients with GERD-like symptoms [142.9 (115.8)]. There were signiﬁ cant differences 
(p  0.01) in adherence to index PPI between BE patients (33.2%), EE patients 
(32.7%), GERD patients (20.7%), and patients with GERD-like symptoms (18.8%).
During the study period, a higher proportion of patients with GERD-like symptoms
(63.6%, p  0.01), GERD (58.2%, p  0.01) and EE (40.3%, p  0.04) discontinued
PPI treatment compared with BE patients (37.9%). CONCLUSIONS: Patients with 
BE and EE, generally considered as a more severe form of GERD, showed higher 
adherence with and lower discontinuation of PPI treatment compared to patients with 
GERD and GERD-like symptoms. Additional studies of the clinical and economic
implications of discontinuing PPI treatment should be conducted.
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OBJECTIVES: Medical errors are a major problem in the United States. The Institute
of Medicine estimates that medical errors cost the U.S. approximately $37.6 billion, 
of which $17 billion are preventable. Our objectives are to develop a Bayesian network 
(BN) model to detect value errors in blood lab and to compare performance of our 
model with an existing automated ruled-based approach (LabRespond), and a logistic 
regression model. METHODS: The sample consisted of 5800 observations from the 
National Health and Nutrition Examination Survey dataset. The performance was 
assessed by the area under the receiver-operating characteristics curves (AUCs) using 
a 10-fold cross validation methodology. Small, medium, and large errors were ran-
domly generated and added to liver enzymes (AST, ALT, and LDH). The outcome of 
interest was the correct detection of liver enzymes as “error” or “normal.” In BN, the
outcome was predicted by exploiting probabilistic relationships among AST, ALT, 
LDH, and gender. Addition to AST, ALT, LDH, and gender, LabRespond required 
more analyte information (GGT, ALP, and total bilirubin) to achieve optimal predic-
tion. For the Logistic model, the model was determined by stepwise selection among 
analytes that were signiﬁ cant at A  0.05. RESULTS: The BN was predictive of added 
errors with small [AUC  0.644 (0.023)], medium [AUC  0.787 (0.019)], and large 
[AUC  0.903 (0.013)] error sizes; and performed signiﬁ cantly better than LabRe-
spond [z  1.99 (p  0.05), z  2.77 (p  0.01), and z  4.57 (p  0.001), respectively]
and the logistic model [z  1.71 (p  0.05), z  5.28 (p  0.001), and z  8.87 (p 
0.001), respectively]. CONCLUSIONS: A BN model detects errors better and with 
less information than existing automated models, suggesting that Bayesian model can 
be an effective means for reducing medical costs in the laboratory
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OBJECTIVES: Retrospective chart review data can be important inputs to economic 
models or other burden of illness evaluations. Traditional paper-based approaches and 
local site monitoring can be cost and time prohibitive. A case study of an efﬁ cient,
adaptable design and electronic data capture methodology for the collection of multi-
national clinical, and resource utilization chart data is presented. METHODS: A ret-
rospective chart review study of patients with CLD, bridging ﬁ brosis, and cirrhosis 
from 10 liver centers (7 US; 3 EU) was conducted (eligibility period  6/1/04 to 
5/31/06; study period  minimum of 12 months). Demographics, clinical and health
economic data were collected. All potentially eligible patients were identiﬁ ed by the
sites, but the ﬁ nal random selection of the target cohort and its disposition was con-
trolled centrally through a web-based tool. RESULTS: Data from 864 patient charts 
(62.8% male; mean age 52.3 years) were abstracted over one year. Data abstraction
spanned 22 to 52 weeks depending on the site and its resources. The standardized
eCRF worked well for the capture of multi-national data. Quality was maintained by
electronic validation rules applied at the point of data entry and shown by data com-
pleteness and a minimum of data queries. Database lock was achieved in less than
three weeks following the last data entry. Remote training of data abstractors by
WebEx proved efﬁ cient. Data have been used successfully to inform clinical trial design
and to estimate the cost of illness. Main challenges included timely contracting of sites,
the need for site-speciﬁ c algorithms to identify charts, and analytical methods tailored
to naturalistic data. CONCLUSIONS: A well designed CRF and web-based cohort
control and data capture tool can provide a practical and efﬁ cient means of collecting 
high quality, multi-national outcomes data without the need for costly site visits and 
local monitoring.
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OBJECTIVES: Since it houses the digestive system, the least sign of digestive problems
shows up in the stomach. Fermentation, carbonated drinks, air swallowed while 
eating, constipation  .  .  .  but also stress or strong emotions: it becomes painful and
bloated. Evaluate the beneﬁ t of using “afﬁ nex ﬂ at stomach” as part of a weight loss 
regime. METHODS: Prospective pragmatic evaluation under real-life conditions. The
pharmacist gave a double questionnaire along with the product to all adult female
customers who had started (or were about to start) a weight loss regimen and who
asked the pharmacy for help or advice. TOOLS Validated questionnaires were used 
(SF 12 and BISS (Body Index States Scale)). Moreover, waist measurement and symp-
toms were assessed and organized in a single score (Pain, Bloating, Belching, Spasm, 
Transit problems, Flatulence and Nausea). RESULTS: A total of 178 female subjects
included, age: 40.8 o 12.3 years with an average BMI of 23.5 o 3.8 kg/m², the score 
of the symptoms was 146. With regards to QoL scales, the average scores on inclusion 
